Molecular Partners Stock
Molecular Partners AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Patrick Amstutz
- Employees
- 134
- Market cap
- $136 M
- IPO
- 16/06/2021
Molecular Partners AG is a clinical-stage biopharmaceutical company specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. Founded in 2004, the company is headquartered in Schlieren, Switzerland, and employs 134 employees. The firm's pipeline consists of various…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Molecular Partners stock: price history
1D
-2.5%
1W
-7.5%
1M
-9.2%
6M
-15.4%
YTD
-18.3%
1Y
-7.5%
2Y
-28.1%
5Y
-82.0%
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~3% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Molecular Partners
Analyst assessment of Molecular Partners
PRICE TARGET LOW
US$13.00
CONSENSUS
US$21.00
MEDIAN
US$21.00
PRICE TARGET HIGH
US$29.00
0
STRONG BUY
1
BUY
3
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Hold
As of: 22/04/2026
Molecular Partners stock metrics
P/E
-2.28
P/B
2.05
EV/EBITDA
-1.09
RETURN ON EQUITY
-23.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.7%
FLOAT SHARES
38,198,937
AVG. DAILY VOLUME (30D)
1,567
Institutional holders
Comparable stocks
Frequently asked questions about Molecular Partners stock
What does Molecular Partners do?
Molecular Partners AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Patrick Amstutz, the company employs around 134 people.
The IPO was on 16/06/2021; the stock trades on NASDAQ under the ticker MOLN.
What do analysts say about Molecular Partners stock?
4 analysts rate the stock, the consensus is Hold (as of 22/04/2026).
The average price target is US$21.00, ranging from US$13.00 to US$29.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does Molecular Partners report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does Molecular Partners pay a dividend?
No, Molecular Partners currently does not pay a dividend.
Which stocks are comparable to Molecular Partners?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get Molecular Partners stock analyzed?
Clicking "Analyze stock" lets five strategies assess Molecular Partners against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.